NASDAQ:KURA Stock Quote
Kura Oncology is a biopharmaceutical company focused on the development of innovative medicines for the treatment of cancer
The company is committed to advancing its proprietary drug candidates that target specific genetic and epigenetic drivers of cancer progression, utilizing their expertise in precision medicine to address unmet medical needs. Through rigorous research and clinical trials, Kura aims to bring transformative therapies to patients suffering from various types of cancer, including rare and hard-to-treat forms. Their goal is to improve outcomes and quality of life for patients by providing targeted treatments that leverage the unique characteristics of their tumors.
Frequently Asked Questions
Has Kura Oncology entered any collaborations?
Yes, Kura Oncology has established collaborations with various academic institutions and other biotechnology companies to enhance its research capabilities and clinical development efforts. These collaborations are designed to leverage shared expertise and resources in the oncology space.
How does Kura Oncology fund its operations?
Kura Oncology funds its operations through a combination of equity financing, grants, and collaborations. As a publicly-traded company, it has the ability to raise funds through public offerings, while also exploring strategic partnerships that can contribute to its financial resources and development capabilities.
How does the company prioritize patient safety?
Kura Oncology prioritizes patient safety by adhering to rigorous clinical trial protocols and regulatory guidelines. They conduct thorough safety assessments during all stages of drug development and continuously monitor adverse events to ensure that their therapies are as safe and efficacious as possible for patients.
Is Kura Oncology a publicly traded company?
Yes, Kura Oncology, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol KURA. The company went public in 2016 through an initial public offering (IPO), which raised capital to support its drug development programs.
What are Kura Oncology's goals for the future?
Kura Oncology aims to advance its pipeline of targeted cancer therapies towards commercialization, expand its clinical development programs, and explore new collaborations. Their goals encompass improving treatment outcomes for cancer patients and achieving significant milestones in their ongoing clinical trials.
What are some of Kura’s lead drug candidates?
Kura’s lead drug candidates include tipifarnib, a farnesyltransferase inhibitor being studied for patients with certain hematological malignancies, and other drug candidates targeting specific genetic mutations found in solid tumors. These candidates are at various stages of clinical development with the goal of moving towards commercialization.
What are some recent milestones achieved by Kura Oncology?
Recent milestones achieved by Kura Oncology include successful interim results from clinical trials, the initiation of new studies, and the advancement of regulatory filings. These milestones contribute to the overall advancement of their drug pipeline and support their mission to develop novel cancer therapies.
What does Kura Oncology, Inc. do?
Kura Oncology, Inc. is a clinical-stage biotechnology company that is committed to developing targeted therapies for the treatment of oncology patients. They focus on advancing a pipeline of novel drug candidates that leverage their deep understanding of cancer biology and drug mechanisms to address unmet medical needs in various tumor types.
What is Kura’s primary therapeutic focus?
Kura Oncology primarily focuses on oncology therapeutics, with an emphasis on developing drug candidates to treat hematologic malignancies and solid tumors. Their research aims to address significant challenges in treating various types of cancer by innovating targeted therapies.
What is Kura’s strategy for drug development?
Kura’s strategy for drug development involves identifying and advancing therapeutic candidates that have a strong scientific rationale and a clear path to regulatory approval. They utilize both internal expertise and partnerships to expedite the clinical development of their therapies, focusing on precision medicine approaches.
What is the company’s approach to precision medicine?
Kura Oncology embraces a precision medicine approach by developing targeted therapies that seek to match specific drugs to the genetic and molecular profiles of individual patients. This method aims to improve treatment efficacy while minimizing side effects, aligning better with the unique biology of each patient’s cancer.
What is the significance of tipifarnib in cancer treatment?
Tipifarnib is significant in cancer treatment as it targets the farnesylation process, which is critical in the activation of several oncogenes. By inhibiting this process, tipifarnib aims to disrupt cancer cell proliferation and survival, offering a new therapeutic option for patients with certain types of malignancies.
What recent clinical trials has Kura Oncology conducted?
Kura Oncology has conducted several clinical trials, including Phase 2 trials evaluating the safety and efficacy of its drug candidates, such as tipifarnib, in patients with specific types of cancer. Results from these trials inform their development strategy and the potential pathways for regulatory approval.
What resources does Kura Oncology provide for investors?
Kura Oncology provides various resources for investors, including regular financial reports, press releases, and updates on clinical trial progress. They maintain a comprehensive investor relations section on their website to keep stakeholders informed about company developments and performance metrics.
What role do early-stage studies play in Kura’s operations?
Early-stage studies, including Phase 1 clinical trials, play a crucial role in Kura’s operations as they help establish the safety, tolerability, and pharmacokinetics of potential drug candidates. These studies are foundational in determining whether a drug can progress to more advanced clinical trials.
When was Kura Oncology founded?
Kura Oncology was founded in 2014. Since its inception, the company has aimed to build a robust pipeline of oncology drug candidates and leverage cutting-edge science to meet the needs of cancer patients throughout their treatment journeys.
Where is Kura Oncology, Inc. located?
Kura Oncology, Inc. has its headquarters located in San Diego, California. This location is central to its strategic initiatives in drug development, as it is situated in one of the leading biotech hubs in the world, allowing access to diverse talent and resources.
Who are Kura Oncology's competitors?
Kura Oncology operates within a competitive landscape that includes other biotechnology companies focused on oncology, such as Mirati Therapeutics, Blueprint Medicines, and Iovance Biotherapeutics. These competitors also strive to develop innovative cancer therapies, which can raise the bar for treatment standards in the industry.
Who is on Kura Oncology's leadership team?
Kura Oncology's leadership team consists of experienced professionals with diverse backgrounds in oncology, drug development, and biotechnology. This team brings together expertise in scientific research, clinical operations, and business strategy to drive the company’s mission forward.
What is the current price of Kura Oncology, Inc. - Common Stock?
The current price of Kura Oncology, Inc. - Common Stock is 6.370
When was Kura Oncology, Inc. - Common Stock last traded?
The last trade of Kura Oncology, Inc. - Common Stock was at 2:01 pm EDT on April 2nd, 2025
What is the market capitalization of Kura Oncology, Inc. - Common Stock?
The market capitalization of Kura Oncology, Inc. - Common Stock is 435.95M
How many shares of Kura Oncology, Inc. - Common Stock are outstanding?
Kura Oncology, Inc. - Common Stock has 68.44M shares outstanding.